75484-47-8

Upstream product

• 132862-06-7 N-(1-benzylpiperidin-4-yl)phenylacetamide 
• 1242436-93-6 C₁₈H₂₆N₂O₃ 

Downstream Products

• 976-65-8 N-(1-phenethyl-piperidin-4-yl)-2-phenyl-acetamide 
• 1242436-66-3 N-{1-[3-(2-oxo-benzooxazol-3-yl)-propyl]-piperidin-4-yl}-2-phenyl-acetamide 
• 1186229-54-8 N-{1-[3-(2-oxo-3,4-dihydro-2H-quinolin-1-yl)-propyl]-piperidin-4-yl}-2-phenyl-acetamide 
• 1242436-52-7 N-{1-[3-(5-fluoro-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-propyl]-piperidin-4-yl}-2-phenyl-acetamide 
• 1242436-54-9 N-{1-[3-(6-fluoro-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-propyl]-piperidin-4-yl}-2-phenyl-acetamide 
• 1242436-56-1 N-{1-[3-(7-fluoro-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-propyl]-piperidin-4-yl}-2-phenyl-acetamide 
• 1242436-58-3 N-{1-[3-(8-fluoro-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-propyl]-piperidin-4-yl}-2-phenyl-acetamide 
• 1186230-10-3 N-{1-[3-(6,7-difluoro-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-propyl]-piperidin-4-yl}-2-phenyl-acetamide 
• 1242436-60-7 N-{1-[3-(6-methoxy-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-propyl]-piperidin-4-yl}-2-phenyl-acetamide 
• 1242436-62-9 N-{1-[3-(7-methoxy-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-propyl]-piperidin-4-yl}-2-phenyl-acetamide 
• 1186229-78-6 N-{1-[3-(3-oxo-2,3-dihydro-benzo[1,4]thiazin-4-yl)-propyl]-piperidin-4-yl}-2-phenyl-acetamide 
• 1610524-09-8 C₄₈H₅₅N₃O₆ 
• 278598-77-9 (2S)-2-{[(2S)-2-({2-[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino}-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl)oxy]phenyl}propanoic acid 
• 278598-81-5 (2S)-2-[((2S)-2-{[2-(2-cyclohexylphenoxy)acetyl]amino}-4-methylpentanoyl)amino]-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl)oxy]phenyl}propanoic acid 

Relevant academic research and scientific papers

Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl] piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An allosteric muscarinic M 1 receptor agonist with unprecedented selectivity and procognitive potential

The discovery and Structure-activity relationship (SAR) of a series of allosteric muscarinic M1 receptor agonists are described. Compound 17 (Lu AE51090) was identified as a representative compound from the series, based on its high selectivity as an agonist at the muscarinic M1 receptor across a panel of muscarinic receptor subtypes. Furthermore, 17 displayed a high degree of selectivity when tested in a broad panel of G-protein-coupled receptors, ion channels, transporters, and enzymes, and 17 showed an acceptable pharmacokinetic profile and sufficient brain exposure in rodents in order to characterize the compound in vivo. Hence, in a rodent model of learning and memory, 17 reversed delay-induced natural forgetting, suggesting a procognitive potential of 17.

COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES

There are provided according to the invention, novel compounds of formula (I)wherein R, R, R, R, Rand Rare as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Synthesis and structure-activity relationships of N-(1-benzylpiperidin-4-yl)arylacetamide analogues as potent σ1receptor ligands

A series of N-(1-benzylpiperidin-4-yl)arylacetamides were synthesized and evaluated for their binding properties for σ1 and σ2 receptors. In agreement with previously reported σ1/σ2 receptor binding data for N-(1-benzylpiperidin-4-yl)phenylacetamide, all of the N-(1-benzylpiperidin-4-yl)arylacetamide compounds reported below displayed higher affinity for σ1 vs σ1 receptors. Replacement of the phenyl ring of the phenylacetamide moiety with a thiophene, naphthyl, or indole aromatic ring had no significant effect on the σ1 receptor affinity. Replacement of the phenyl ring with an imidazole or pyridyl aromatic ring resulted in a >60-fold loss in affinity for σ1 receptors and no significant binding affinity for σ2 receptors. Substitution on the aromatic ring of the benzyl group showed a similar or slightly decreased affinity for σ1 receptors. Substitution on the aromatic rings of both the phenylacetamide moiety and the benzyl group with a halogen resulted in a similar affinity for σ1 receptors and a significantly increased affinity for σ2 receptors. Comparative molecular field analysis revealed that electrostatic properties of the substituents in the phenylacetamide aromatic ring strongly influenced binding to σ1 receptors. Compounds 1, 10, 18, 22, 37, and 40 showed the highest selectivity for σ1 receptors with Ki (σ2) to Ki (σ1) ratios of 100, >92, >122, 77, 74, and 80, respectively. In agreement with previously reported results, the phenylacetamide analogues had no binding affinity for dopamine receptors (D2/D3).